Nav: Home

JAK inhibitors associated with aggressive lymphoma

June 15, 2018

(WASHINGTON, June 15, 2018) -- Austrian researchers have discovered that a small number of patients taking targeted drugs known as Janus kinase (JAK) inhibitors to treat myelofibrosis may develop aggressive lymphomas.

They also speculate that screening for a preexisting B-cell clone before starting therapy may help prevent this side effect and potentially save lives, according to a study published online today in Blood, the Journal of the American Society of Hematology (ASH).

One of three disorders that falls under the umbrella of myeloproliferative neoplasms is myelofibrosis, a rare bone marrow cancer in which too many blood cells are produced, leading to scarring and hardening inside the bone marrow. The exact cause of myelofibrosis is not known, but it has been linked to the JAK2 gene, which control the production of blood cells. Doctors treat the condition with medications designed to target or inhibit the action of this gene when it is faulty.

Though not a cure, JAK inhibitors are very effective at providing symptom relief, said study coauthor Heinz Gisslinger, MD, of the Medical University of Vienna in Austria. "However, we started noticing sporadic cases of lymphomas developing in patients being treated for myeloproliferative neoplasms and wanted to know if this phenomenon was connected to treatment."

To test this, investigators assessed 626 patients receiving treatment for myeloproliferative neoplasms at the Medical University of Vienna and identified 69 that had myelofibrosis and were being treated with JAK inhibitors. Of those, four (5.8%) developed lymphomas. In comparison, they found that of the 557 patients who did not receive JAK inhibitors, only two (0.36%) developed lymphomas.

That amounts to a 16-fold increased risk for aggressive B-cell lymphoma in patients receiving JAK inhibitors, said study coauthor Ulrich Jäger, MD, of the Medical University of Vienna.

In samples taken from the patients with myelofibrosis, investigators found a preexisting B-cell clone in the bone marrow in three of the four patients who later developed lymphoma. Further investigation suggested that this clone was the same that later transformed into lymphoma.

The investigators also demonstrated an association between JAK inhibition and an increased frequency of aggressive B-cell lymphomas in mouse models.

"By replicating this link between this B-cell clone and aggressive lymphoma, we hope to speed the discovery of an alternative therapy for myelofibrosis," said study coauthor Veronica Sexl, MD, of the University of Veterinary Medicine, Vienna. "These findings are going to be valuable in clinical care."

"We determined that patients with this preexisting B-cell clone in their bone marrow are most at risk for developing aggressive lymphoma," said Dr. Jäger. "We also know that up to 16 percent of people with myelofibrosis have immunoglobulin gene rearrangements like this B-cell clone. Therefore, our findings suggest that all patients with myelofibrosis should be tested for such gene rearrangements before prescribing JAK inhibitors to treat their disease."
-end-
Blood, the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is a journal of the American Society of Hematology (ASH) , the world's largest professional society concerned with the causes and treatment of blood disorders.

ASH's mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.

blood® is a registered trademark of the American Society of Hematology.

Contact:

Stephen Fitzmaurice
American Society of Hematology
sfitzmaurice@hematology.org; 202-552-4927

American Society of Hematology

Related Lymphoma Articles:

The gene behind follicular lymphoma
EPFL scientists have discovered an important gene whose loss lies behind follicular lymphoma, an incurable cancer.
Hodgkin lymphoma survivors at high risk of second cancers
Patients who are cured of Hodgkin lymphoma are at a high risk of developing a second type of cancer, particularly if they have a family history of the disease, a major new study reports.
Follicular lymphoma: A tale of 2 cancers
Many people survive well beyond 10 years following diagnosis of follicular lymphoma.
Patients with advanced lymphoma in remission after T-cell therapy
In a paper published today in Science Translational Medicine, researchers from Fred Hutchinson Cancer Research Center shared data from an early-phase study of patients with advanced non-Hodgkin lymphoma (NHL) who received JCAR014, a Chimeric Antigen Receptor (CAR) T cell treatment, and chemotherapy.
$2.5 million boost for lymphoma research through Tanoto Foundation
The SingHealth Duke-NUS Academic Medical Centre announced today that a S$2.5 million Tanoto Foundation Professorship in Medical Oncology has been conferred to Assoc Prof Lim Soon Thye, Head and Senior Consultant of the Division of Medical Oncology at the National Cancer Centre Singapore; and Assistant Dean at Duke-NUS Medical School.
Lymphoma overrides a key protein's quadruple locks
Protein chemists at Johns Hopkins report they are closer to explaining why certain blood cancers are able to crack a molecular security system and run rampant.
Study: Bacterium that causes Q fever linked to non-Hodgkin lymphoma
The bacterium that causes Q fever, an infectious disease that humans contract from animals, is associated with an increased risk of lymphoma, according to a study published online today in Blood, the Journal of the American Society of Hematology.
Lymphoma: How the tumor escapes the immune response
Natural killer cells of the immune system can fend off malignant lymphoma cells and thus are considered a promising therapeutic approach.
Follow-up PET/CT more than 95 percent sensitive for non-Hodgkin lymphoma
Non-Hodgkin lymphoma, a potentially devastating cancer of the blood and immune system, can range from relatively easy to treat to very aggressive.
Hodgkin's lymphoma: The treatment can have late sequelae
Hodgkin's lymphoma -- cancer of the lymph nodes -- arises in more than 150 children and adolescents in Germany each year.

Related Lymphoma Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Bias And Perception
How does bias distort our thinking, our listening, our beliefs... and even our search results? How can we fight it? This hour, TED speakers explore ideas about the unconscious biases that shape us. Guests include writer and broadcaster Yassmin Abdel-Magied, climatologist J. Marshall Shepherd, journalist Andreas Ekström, and experimental psychologist Tony Salvador.
Now Playing: Science for the People

#513 Dinosaur Tails
This week: dinosaurs! We're discussing dinosaur tails, bipedalism, paleontology public outreach, dinosaur MOOCs, and other neat dinosaur related things with Dr. Scott Persons from the University of Alberta, who is also the author of the book "Dinosaurs of the Alberta Badlands".